An adaptive trial design to optimize dose-schedule regimes with delayed outcomes

DOI10.1111/BIOM.13116MaRDI QIDQ5128802zbMATH OpenOpenAlexWikidataFDO

Authors Ruitao Lin, Peter F. Thall, Ying Yuan

Publication date 26 October 2020

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1111/biom.13116

zbMATH Keywords

missing dataadaptive randomizationoptimal treatment regimeBayesian designphase I-II clinical trialordered subgroups

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Missing data (62D10) Response surface designs (62K20)

Recommendations

• A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
• Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
• Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes

Cited in

(6)

• A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages
• A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups
• Change-point joint model for identification of plateau of activity in early phase trials
• Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers
• A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
• Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes

This page was built for publication: An adaptive trial design to optimize dose-schedule regimes with delayed outcomes

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5128802)